



Short Communication

Cloning and Expression of Interleukin 11 in *Bacillus subtilis*Atena Azarniush¹, Majid Moghbeli^{2*}, Farshid Kafilzadeh¹, Mohammad Kargar¹ and Hooshang Jamali¹¹Department of Microbiology, Islamic Azad University, Jahrom Branch, Jahrom, Iran²Department of Biology, Islamic Azad University, Damghan Branch, Damghan, Iran

ABSTRACT

Cancer is considered as the second leading cause of death in the world. The decreased platelet count is one of the major problems that patients face through the treatment, which makes them prone to bleeding. PRP injection therapy is a therapeutic method in use to relieve this condition. It may lead to infections due to the injection, as well as platelet resistance. Therefore, an attempt was made to find an alternative treatment, and the recombinant Interleukin 11 (IL-11). In this study, IL-11 gene owning two restriction enzyme sites of BamHI and XbaI with a final size of 609 bp was synthesized by GenRay (China) and delivered to pGS vector. The vector was transferred to DH5 α , then the gene was subcloned onto pHT43 shuttle vector and transformed into the *Bacillus subtilis* WB600. The vector containing the cloned gene was induced within the WB600 by IPTG. The SDS-PAGE also indicated the successful expression of IL-11 in *B. subtilis*. A band of about 22 kD corresponding to the recombinant protein was observed in positive sample. This research demonstrated the efficacy of using *B. subtilis* as an expression system for the production of IL-11 and it can be used as a candidate for the proteins without post-translational modification.

Article Information

Received 03 July 2021

Revised 21 December 2021

Accepted 05 January 2022

Available online 17 June 2022

(early access)

Authors' Contribution

MM planned the proposed study. AA, MM contributed to the lab work. FK, AA, MK and HJ wrote the article.

Key words

Interleukin-11 (IL-11), Gene expression, *Bacillus subtilis*, Shuttle vector

Cancer is considered as the second leading cause of death in the world. Chemotherapy is the most important therapeutic method in patients with cancer. The decreased platelet count is one of the major problems that patients face through the treatment, which makes them prone to bleeding and endangers their lives. Platelet-rich plasma (PRP) injection therapy is a therapeutic method in use to relieve this condition. However, it may lead to infections due to the injection, as well as platelet resistance. Therefore, an attempt was made to find an alternative treatment, and the recombinant Interleukin 11 (IL-11) (Putoczki and Ernst, 2015). Human IL-11 is a Pleiotropic cytokine derived from stromal cells or support cells in the bone marrow, belonging to the IL-6-type cytokine family (Murakami *et al.*, 2019). When the tissue is damaged or infection occurs, IL-6 is rapidly stimulated and synthesized, and through the reaction of the body's

immune system, the acute phase helps the host to defend (Tanaka and Kishimoto, 2014). In addition, studies have shown that mesenchymal stem cells also have the potential to synthesize and secrete IL-11 cytokines (Liu *et al.*, 2013). Human IL-11 gene is 7 kb in length consisting five exons and four introns, which is located on the long arm of chromosome 19, and at band 19q13.3-q13.4. It is coded with 199 amino acids and encodes a 23 kDa protein with a high isoelectric point without cysteine (Fung *et al.*, 2022; Hill *et al.*, 1998). IL-11 also opposes the proinflammatory mechanisms leading to sepsis, preserves neurological function following cerebral ischemia-reperfusion injury, upregulates the proteins involved in the acute phase response, and induces lymphocyte differentiation (Brocker *et al.*, 2010; Ryter *et al.*, 2006; Zhang *et al.*, 2019). Damaged hepatocytes produce IL-11 which in turn stimulates the proliferation of healthy hepatocytes (Lokau *et al.*, 2017). Furthermore, the IL-11 cytokine stimulates the process of platelet production by inducing megakaryocyte differentiation (Takahashi *et al.*, 2007). In 2006, IL-11 was approved by the Food and Drug Administration (FDA) for the treatment of thrombocytopenia (Ciurea and Hoffman, 2007). *Bacillus subtilis* is known as a prokaryotes host for the expression of foreign proteins with medicinal or immunological properties. Unlike *Escherichia coli*, *B. Subtilis* has no Lipopolysaccharides (LPS) in its outer membrane. In addition, it has a high capacity of secretion

* Corresponding author: dr.majidmoghbeli@yahoo.com
0030-9923/2022/0001-0001 \$ 9.00/0



Copyright 2022 by the authors. Licensee Zoological Society of Pakistan.

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

to transfer the protein into the medium, which facilitates the purification process (Guan *et al.*, 2016).

In this study, *B. subtilis* was used to produce the recombinant IL-11. *B. subtilis*, is considered an appropriate host for gene cloning and protein expression, due to non-pathogenicity and the ability to secrete high protein levels (Luan *et al.*, 2014). Accordingly, it is better to perform the cloning steps first using a shuttle vector in *E. coli*, followed by transforming *B. subtilis* (Ferreira *et al.*, 2005).

Considering the importance of recombinant IL-11, the aim of this study was to clone and express human IL-11 gene to produce IL-11. Due to the high cost of the commercial recombinant IL-11 (Neumega), the laboratory production of the recombinant IL-11 can be a useful step in the production of this valuable medication.

Materials and methods

The sequence of IL-11 was obtained from NCBI database, the peptide signal sequence was removed, and also the *Bam*HI site was placed at the beginning, and the *Xba*I site at the end of the gene. The sequence was then optimized for codon usage based on *B. subtilis* using J-CAT software to increase expression. The gene with a final size of 609 bp was synthesized (GenRay Co, China) and delivered on the pGS vector.

The IL-11 gene was cut from the pGS vector through digestion by *Bam*HI and *Xba*I enzymes and purified from the agarose gel by DNA purification kit (Pouya Gene Azma Co. Iran). Then it was subcloned on the *Bam*HI and *Xba*I sites of pHT43 *B. subtilis* shuttle vector (MoBiTec, Germany). The ligation reaction transferred to the *E. coli* (DH5 α) using heat shock method. The presence of the gene on the plasmid was evaluated by enzymatic digestion and Polymerase Chain Reaction (PCR).

The recombinant plasmid carrying the gene was named pHT-MA52. The recombinant plasmid pHT-MA52 was isolated using plasmid purification kit (Pouya Gene Azma Co. Iran) from *E. coli* (DH5 α) and transferred to *B. subtilis* (WB600) using the Optimized Transformation Buffer (OTB) containing: 0.75 g/l yeast extract; 8 g/l glucose; 1.0 mM CaCl₂, and 10 mM MgCl₂; pH 7.0. The recombinant bacteria were inoculated in 5 ml of MFA medium (1% glucose, 0.5% peptone, 0.5% yeast extract, 0.01%, MgSO₄, 0.014% CaCl₂, 0.001% FeSO₄, 5 μ g/ml chloramphenicol) and Luria-Bertani (LB) broth and incubated for 2.5-3 h at 37°C by shaking until the turbidity reached about 0.6-0.8 at wavelength of 600 nm. Recombinant protein expression was induced by adding Isopropyl β -D-1-thiogalactopyranoside (IPTG) to the final concentration of 1 mM. Prior to the induction and with an hour intervals after induction, 300 μ l of the medium was withdrawn for 6 h. The bacterial cells were separated

centrifuging at 11400 g for 3 min and the supernatant was stored at 4°C until the next step. The protein concentration of each sample was evaluated using the Bradford protein assay (He, 2011). As the negative control (blank), the supernatant of *B. subtilis* carrying pHT43 plasmid without the gene was used. The recombinant protein band was examined by 12% SDS-PAGE.

Results

Figure 1 shows the sequence of the designed and synthesized interleukin 11 gene based on the used codons in *B. subtilis*.

```

GGATCCAAC TGC GTT TGC GCT TGT TCT TGT TGT TCT TCT TCT TGG CC      50
TGATACAG CTGTG C TCC TGG CCC TCC TCC TGG CCC TCC TCG GTT TCC      100
CTGATCCT CGT GCT GAA CTT GATT CTACAG TCT TCT TACACG TCTCTCT      150
CTTGTGTA TACACG TCAACT TGTGCTCAACT TCGTGATAAAAT TCCCTGC      200
TGATGGCG ATCATAAC CTTGATTCTCTCTACACT TGTATGTCTGTGCTG      250
GCGCTCTT GGGCCTCTTCAACT TCTGGCGTCTTACACG TCTTCGTGCT      300
GATCTTCT TTTCTTACCT TCGTCATGTTCAATGGCTTCGTCGTGCTGGCGG      350
CTCTTCTC TTTAAAACACTTGAACCTGAACTTGGCACACTTCAAGCTCGTC      400
TTGATCGT CTCTTCGTCGCTTCAACTTCTTATGTCGTCGCTTGTCTTT      450
CCTCAACCT CCTCTGATCCCTCGTCTCTCTCTCTTGTCTCTCTCTCTCTC      500
TGCTTGGG GCGGCATCCGTCGTGCTCATGCTATCCTTGGCGGCCTTCATC      550
TTACACTT GATTGGGCTGTTGCTGGCC TCTCTCTCTTAAAACACGCTCT      600

```

Fig. 1. The sequence of the designed and synthesized interleukin 11 gene based on the codon usage in *B. subtilis*: The underlined sequences are restriction sites: 5' end and 3' end respectively belongs to *Bam*HI and *Xba*I.

Figure 2 shows the following enzymatic digestion of the gene from the pGS vector. The gene was cloned in *B. subtilis* using pHT43 vector. The presence of the gene in the vector was confirmed by double digestion using *Bam*HI and *Xba*I as well as PCR.




Fig. 2. A, Double digestion of the plasmid pHT43 containing *IL-11* gene: lane 1: 1 kb plus DNA ladder; lane 2: double digested recombinant plasmid. B, PCR of the recombinant plasmid pHT-MA52: lane 1: negative control. Lane 2: PCR product. Lane 3: 1 kb plus DNA ladder.

The expression yield was measured both in LB and MFA media. As shown in Table I, the expression level in MFA medium was higher than LB medium (61.4 $\mu\text{g/ml}$ in MFA and 21.8 $\mu\text{g/ml}$ in LB). In addition, highest expression level was obtained in both media 4 h after IPTG induction. The MFA medium sample 4h after induction, and the medium sample of the pHT-43 without IL-11 gene were evaluated on SDS-PAGE. A band of about 22 kDa corresponding to the recombinant protein was observed in the test sample, whereas no bands were observed in the negative control (Fig. 3).

Table I. Interleukin 11 recombinant protein expressed in LB and MFA media 6h after IPTG induction. The expression level is expressed as $\mu\text{g/ml}$ of the culture medium.

Hour	LB	MFA
First	3.6	18.8
Second	16.3	35.6
Third	21.8	49.1
Fourth	24.1	61.4
Fifth	22.9	58.1
Sixth	22	54.7



Fig. 3. Evaluation of the recombinant protein band on SDS-PAGE: lane 1: negative control, lane 2: recombinant protein, lane 3: protein ladder.

Discussion

Chemotherapy-induced thrombocytopenia limits the therapeutic utilization of chemotherapeutic agents, and may adversely affect the outcome of potentially treatable

malignancies. IL-11 is the first thrombopoietic cytokine made commercially available for the treatment of Chemotherapy-induced thrombocytopenia (Reynolds, 2000). While IL-11 appears to contribute to a host of regulatory pathways including the stimulation of myeloid and erythroid precursors as well as modulating macrophage and T cell inflammatory responses, stimulation of thrombopoiesis is regarded as the primary function of IL-11 (Wu *et al.*, 2012). The thrombopoietic effect of IL-11 is exerted in all stages of megakaryocyte maturation (Feinglass *et al.*, 2001). Previously presumed thrombopoietin (TPO) independent effect of IL-11 has been shown to fail in TPO- or TPO receptor-deficient subjects, implicating potential role of TPO signaling in IL-11 pathways (Avecilla *et al.*, 2004; Feinglass *et al.*, 2001). IL-11 induces the recovery of progenitor cells belonging to multiple hematopoietic lineages in myelosuppressed subjects (Hill *et al.*, 1998).

The aim of this study is cloning and expression of Interleukin 11 in *Bacillus subtilis* in order to produce this valuable cytokine in lab scale. Till now, the gene of IL-11 has been cloned and expressed in different pro- and eukaryotic hosts such as human endometrium, tobacco and *E. coli* (Karpovich *et al.*, 2003; Sadeghi *et al.*, 2016; Sokolov *et al.*, 2016). Here, for the first time the gene of IL-11 is cloned and expressed in *B. subtilis*. Every expression system has its own pros and cons and the suitable system has to be selected based on the target protein. High capacity of secretion, direct secretion of the recombinant protein in medium, as well as safe and easy culture condition of *B. subtilis*, made it an appropriate host for gene cloning and expression (Rashidi and Moghbeli, 2013). In different studies, gene of IL-11 has been obtained using mRNA extraction, cDNA syntheses and PCR amplification. In this paper, IL-11 was designed and optimized for codon usage of *B. subtilis* by J-CAT software. The designed gene was then synthesized and cloned in pHT43. The recombinant protein expression after IPTG induction led to expression of a 22 KD protein like other researches. The recombinant IL-11 expression was extracellular, about 61.4 $\mu\text{g/ml}$ and more than the expression yield in *E. coli*, so this host is suggested for the recombinant IL-11 production.

Conclusion

This study demonstrated the efficacy of using *B. subtilis* as an expression system for production of IL-11 and it can be used as a candidate for the production of every recombinant protein which lacks post-translational modifications.

Acknowledgements

Our sincere thanks to Pouya Gene Azma Co, Tehran,

Iran, for providing facilities to carry out the experiments and Azad University of Jahrom branch for their help during this research.

Statement of conflict of interest

The authors have declared no conflict of interest.

References

- Avecilla, S.T., Hattori, K., Heissig, B., Tejada, R., Liao, F., Shido, K., Jin, D.K., Dias, S., Zhang, F. and Hartman, T.E.J.N., 2004. *Nat. Med.*, **10**: 64-71. <https://doi.org/10.1038/nm973>
- Brocker, C., Thompson, D., Matsumoto, A., Nebert, D.W. and Vasilidou, V.J.H.G., 2010. *BMC*, **5**: 1-26. <https://doi.org/10.1186/1479-7364-5-1-30>
- Ciurea, S.O. and Hoffman, R., 2007. *Cytokines for the treatment of thrombocytopenia*, *Cience direct*. Elsevier, pp. 166-182. <https://doi.org/10.1053/j.seminhematol.2007.04.005>
- Cremer, M., Sallmon, H., Kling, P.J., Bühner, C. and Dame, C., 2016. *Thrombocytopenia and platelet transfusion in the neonate, seminars in fetal and neonatal medicine*. Elsevier, pp. 10-18. <https://doi.org/10.1016/j.siny.2015.11.001>
- Feinglass, S., Deodhar, A.J.A. and Rheumatology, R.O.J., 2001. *Off. J. Am. Coll. Rheumatol.*, **44**: 170-175. [https://doi.org/10.1002/1529-0131\(200101\)44:1<170::AID-ANR22>3.0.CO;2-T](https://doi.org/10.1002/1529-0131(200101)44:1<170::AID-ANR22>3.0.CO;2-T)
- Ferreira, L., Ferreira, R.C. and Schumann, W., 2005. *Annl's Braz. Acad. Sci.*, **77**: 113-124. <https://doi.org/10.1590/S0001-37652005000100009>
- Fung, K.Y., Louis, C., Metcalfe, R.D., Kosasih, C.C., Wicks, I.P., Griffin, M.D. and Putoczki, T.L.J.C., 2022. *Sci. Direct*, pp. 155750. <https://doi.org/10.1016/j.cyto.2021.155750>
- Guan, C., Cui, W., Cheng, J., Liu, R., Liu, Z., Zhou, L. and Zhou, Z.J.N.b., 2016. *Sci. Direct*, **33**: 372-379. <https://doi.org/10.1016/j.nbt.2016.01.005>
- He, F.J.B., 2011. *Bradford protein assay*. *bio_protocol*, pp. e45-e45. <https://doi.org/10.21769/BioProtoc.45>
- Hill, G.R., Cooke, K.R., Teshima, T., Crawford, J.M., Keith, J.C., Brinson, Y.S., Bungard, D. and Ferrara, J.J.T.J., 1998. *J. clin. Invest.*, **102**: 115-123. <https://doi.org/10.1172/JCI3132>
- Karpovich, N., Chobotova, K., Carver, J., Heath, J.K., Barlow, D.H. and Mardon, H., 2003. *Basic Sci. Reprod. Med.*, **9**: 75-80. <https://doi.org/10.1093/molehr/gag012>
- Liu, R., Yang, Y., Yan, X. and Zhang, K.J.D., 2013. *Eur. J. Dermatol.*, **23**: 600-607. <https://doi.org/10.1684/ejd.2013.2149>
- Lokau, J., Agthe, M., Flynn, C.M. and Garbers, M.C.R., 2017. *Sci. Direct*, **1864**: 2105-2117. <https://doi.org/10.1016/j.bbamcr.2017.06.008>
- Luan, C., Zhang, H.W., Song, D.G., Xie, Y.G., Feng, J. and Wang, Y.Z.J.A.M., 2014. *Springer*, **98**: 3651-3658. <https://doi.org/10.1007/s00253-013-5246-6>
- Murakami, M., Kamimura, D. and Hirano, T.J.I., 2019. *Sci. Direct*, **50**: 812-831. <https://doi.org/10.1016/j.immuni.2019.03.027>
- Putoczki, T.L. and Ernst, M., 2015. *Immunotherapy*, **7**:4. <https://doi.org/10.2217/imt.15.17>
- Rashidi, M.R. and Moghbeli, M.M.W., 2013. *J. Microbial. World*, **6**: 188-197.
- Reynolds, C.H.J.O., 2000. *Eur. PMC*, **14**: 32-40.
- Ryter, S.W., Alam, J. and Choi, A.M.J., 2006. *Am. Physiol. Soc.*, **86**: 583-650. <https://doi.org/10.1152/physrev.00011.2005>
- Sadeghi, A., Mahdieh, M. and Salimi, S.J.P.B., 2016. *J. Pl. Biotechnol.*, **43**: 432-437. <https://doi.org/10.5010/JPB.2016.43.4.432>
- Sokolov, A.S., Kazakov, A.S., Solovyev, V.V., Ismailov, R.G., Uversky, V.N., Lapteva, Y.S., Mikhailov, R.V., Pavlova, E.V., Terletskaia, I.O. and Ermolina, L.V.J.M., 2016. *Molecules*, **21**: 1632. <https://doi.org/10.3390/molecules21121632>
- Takahashi, T., Shimizu, H., Morimatsu, H., Inoue, K., Akagi, R., Morita, K. and Sassa, S.J.M., 2007. *Eur. PMC*, **7**: 745-753. <https://doi.org/10.2174/138955707781024517>
- Tanaka, T. and Kishimoto, T.J.C., 2014. *Cancer Immunol. Res.*, **2**: 288-294. <https://doi.org/10.1158/2326-6066.CIR-14-0022>
- Wu, S., Zhang, Y., Xu, L., Dai, Y., Teng, Y., Ma, S., Ho, S.-H., Kim, J.-M., Yu, S.S. and Kim, S.J., 2012. *Springer*, **20**: 1875-1884. <https://doi.org/10.1007/s00520-011-1290-x>
- Zhang, B., Zhang, H.-X., Shi, S.-T., Bai, Y.-L., Zhe, X., Zhang, S.-J. and Li, Y.J.J.B., 2019. *Sci. Direct*, **115**: 108816. <https://doi.org/10.1016/j.biopha.2019.108816>